Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

BofA analyst Jason Zemansky lowered the firm’s price target on Travere Therapeutics (TVTX) to $27 from $31 and keeps a Buy rating on the shares ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a ...

Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS ...

Ratings for Travere Therapeutics (NASDAQ:TVTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation ...

Travere Therapeutics, Inc.'s Filspari received full FDA approval last September, due to its significantly reducing kidney function decline in IgA nephropathy, which boosted the company's share ...